Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Colomer

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Cancer|April 15, 1995
Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapyE Felip, J M Del Campo, D Rubio, et al.
Breast Cancer Research and Treatment|March 1, 1989
Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesR Colomer, A Ruibal, J Genollá, et al.
Cancer|January 9, 2001
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapyA Lluch, B Ojeda, R Colomer, et al.
Gynecologic Oncology|April 1, 1994
Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatmentJ M Del Campo, E Felip, D Rubio, et al.
Seminars in Oncology|December 1, 1995
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary resultsR Hitt, J Hornedo, R Colomer, et al.
Breast Cancer Research and Treatment|November 25, 2017
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBCR Colomer, P Hall, M Szkultecka-Debek, et al.
Revista Clinica Espanola|November 19, 2003
[Generalized cutaneous-nodal metastatic spread as initial manifestation of the recurrence of a gastric adenocarcinoma]A Sánchez-Muñoz, C Gravalos Castro, R Colomer Bosch, et al.
Seminars in Oncology|February 1, 1997
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancerR Hitt, J Hornedo, R Colomer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 23, 2021
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumoursP Garrido, R Hladun, E de Álava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
It is not time to stop progesterone receptor testing in breast cancerR Colomer, M Beltran, J Dorcas, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Cancer|April 15, 1995
Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapyE Felip, J M Del Campo, D Rubio, et al.
Breast Cancer Research and Treatment|March 1, 1989
Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseasesR Colomer, A Ruibal, J Genollá, et al.
Cancer|January 9, 2001
Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapyA Lluch, B Ojeda, R Colomer, et al.
Gynecologic Oncology|April 1, 1994
Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatmentJ M Del Campo, E Felip, D Rubio, et al.
Seminars in Oncology|December 1, 1995
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary resultsR Hitt, J Hornedo, R Colomer, et al.
Breast Cancer Research and Treatment|November 25, 2017
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBCR Colomer, P Hall, M Szkultecka-Debek, et al.
Revista Clinica Espanola|November 19, 2003
[Generalized cutaneous-nodal metastatic spread as initial manifestation of the recurrence of a gastric adenocarcinoma]A Sánchez-Muñoz, C Gravalos Castro, R Colomer Bosch, et al.
Seminars in Oncology|February 1, 1997
Study of escalating doses of paclitaxel plus cisplatin in patients with inoperable head and neck cancerR Hitt, J Hornedo, R Colomer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 23, 2021
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumoursP Garrido, R Hladun, E de Álava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2005
It is not time to stop progesterone receptor testing in breast cancerR Colomer, M Beltran, J Dorcas, et al.
Pageof 10